In Group Holdings has invested in Thrixen — an innovative Singapore-based biotech company advancing the future of rapid diagnostics.
Thrixen has developed a novel protein-engineering diagnostic platform that enables multiplex tests at the point of care. By replacing traditional antibodies with engineered protein binders, the platform delivers exceptional performance, including 99.5% sensitivity in earlier clinical trials for COVID-19 immunity detection.
Today, the team is deploying this technology to address a critical clinical challenge: distinguishing between bacterial and viral infections within 10 minutes from a simple finger-prick sample. This has profound implications for frontline care — enabling physicians to personalize treatment decisions rapidly, reduce unnecessary antibiotic use, and improve patient outcomes.
Beyond COVID-era validation, Thrixen is partnering with the Biomedical Advanced Research and Development Authority (BARDA) to develop a multiplex, rapid point-of-care diagnostic platform for Ebola and Malaria. Designed to operate using fingerstick blood samples without complex processing, the system will be portable and battery-powered, making it suitable for deployment in remote and resource-limited environments. This is technology with real-world, lifesaving potential.
Thrixen is backed by strong believers in science-driven innovation, including 22Health Ventures and John Ballantyne, co-founder of Aldevron — further validation of the platform’s technical credibility and global relevance.
We’re also grateful to NTUitive (especially Manish Sinha & David Shem Tov) for inviting In Group to the “Next-Gen Diagnostics for Precision Care” showcase, where we had the opportunity to meet the Thrixen team and learn more about their groundbreaking platform firsthand.
At In Group, we remain committed to backing deep-tech ventures with breakthrough potential and real-world impact. Thrixen’s platform sits at the intersection of advanced protein engineering, rapid diagnostics, and global health security — and we’re proud to support the team as they scale
